Case Rep Oncol 20125181186 DOI 101159000336481 Published online April 18 2012 2012 S Karger AG Basel ISSN 16626575 wwwkargercomcro 181 This Open Access article licensed terms Creative Commons AttributionNonCommercialNoDerivs 30 License wwwkargercomOAlicense applicable online version article Distribution noncommercial purposes PSA Response Lenalidomide Therapy PreTreated Patient Metastatic Prostate Cancer Refractory Hormones Chemotherapy A Case Report Joan Manel Gasent Blesaa Miguel Peris Godoyb María Fonfría Esparciaa Sara Blasco Molláa Balbino Mancheño Magánc José Miguel Sempere Ortellsd José Luis Sáncheze Departamentos aOncología Médica y bMedicina Interna Hospital Dénia Marina Salud Dénia Departamentos cQuímica Orgánica y dInmunología Universidad Alicante Alicante y eDepartamento Ética Universidad Católica Valéncia Valéncia España Key Words Hormoneresistant prostate cancer Prostate serum antigen Lenalidomide Abstract Hormoneresistant prostate cancer HRPC occurs prostate cancer longer responsive hormone therapy Treatment options limited clear necessity therapies improve outcome Preclinical clinical evidence supports role immunomodulatory agent lenalidomide HRPC In paper report lenalidomide showed antitumoral activity patient HRPC bone metastases pretreated chemotherapy decreased PSA level improved patients health status 5 months It important emphasize associated hematologic toxicity Introduction Prostate cancer common cancer second leading cause cancer death men 1 Androgen deprivation therapy treatment choice patients advanced metastatic disease progression typically occurs 12 Joan Manel Gasent Blesa Hospital Dénia Marina Salud Partida la Xara sn ES03700 Dénia Spain Tel 34 96 642 9000 EMail joanmagasent telefonicanet Case Rep Oncol 20125181186 DOI 101159000336481 Published online April 18 2012 2012 S Karger AG Basel ISSN 16626575 wwwkargercomcro 182 years initial response 2 3 Secondary hormonal therapy option patients neoplasms ultimately progress situation androgen independent growth hormoneresistant prostate cancer HRPC androgen independent prostate cancer recently castrationresistant prostate cancer Clinical manifestations include rising PSA prostate serum antigen concentration bone metastases substantive pain softtissuelymph node metastases 4 Some forms HRPC treatment systemic radiation therapy chemotherapy immunotherapy estrogen therapy However outcomes HRPC poor novel agents needed improve treatment condition Many approaches drugs target specific pathways involved cell signaling proliferation apoptosis immune modulation angiogenesis currently investigation improve survival benefit Lenalidomide thalidomide analog known member socalled immunomodulatory drugs IMiDs immunomodulatory antiangiogenic properties In preclinical studies lenalidomide demonstrated antitumoral activity inhibiting hypoxiainduced factor1α expression endothelial cells epithelial tumor cells including prostate cells 5 increase PC3 prostate cancer cell apoptosis monotherapy combination docetaxel 6 Using vitro vivo models prostate cancer lenalidomide inhibited growth factorinduced invasion produced synergistic effects combination docetaxel slowed tumor progression 7 The published reports use lenalidomide combination HRPC patients 817 clear evidence clinical antitumoral activity disease In paper demonstrate lenalidomide antitumoral activity associated hematologic toxicity Case Report In paper discuss case 65yearold male patient diagnosed August 1999 transurethral resection prostate Gleason 610 prostate adenocarcinoma His past medical history included renal clear cell adenocarcinoma kidneys constipation treated lactulose The serum PSA time diagnosis elevated 197 ngml normal range 00 40 Radiotherapy combined androgen blockade CAB therapy initiated comprising lutein releasing hormone analog Zoladex bicalutamide 50 mg daily table 1 The patient remained asymptomatic low PSA level 5 years PSA nadir 01 ngml In January 2008 biochemical bone progression diagnosed increased PSA 12 ngml bone metastases detected bone CT scans A similar scheme hormonal therapy CAB administered The patient castration testosterone levels 50 ngml However 3 months later PSA rose 37 ngml In April 2008 patient referred department HRPC boneonly metastases The patient received hormonal therapy cyproterone acetate 2 months biochemical progression detected new increase PSA 64 ngml Subsequently docetaxelprednisonebased chemotherapy started patients PSA level rose initial drop 64123857 ngml bone CT scans showed boneonly metastases In October secondline chemotherapy oxaliplatin capecitabine compassionateuse basis administered 3 cycles treatment PSA level 233 ngml In November 2008 therapy replaced treatment fulvestrant compassionate use month PSA level returned 32 ngml However March 2009 PSA value higher 300 ngml Sunitinib proposed compassionate use After treated 5 months sunitinib 50 mg daily days 14 given 42 days serum PSA level rose 749 ngml Soon August 2009 patient began treatment vinblastineAdriamycinestramustine ketoconazole Case Rep Oncol 20125181186 DOI 101159000336481 Published online April 18 2012 2012 S Karger AG Basel ISSN 16626575 wwwkargercomcro 183 discontinued cycle given clinical deterioration associated intense pain initial PS 1 final PS 2 increased levels serum PSA 1146 ngml In October patient received antalgic radiotherapy bone metastases A new line treatment lenalidomide 25 mgday compassionate use analgesic agents administered November 2009 Concomitant analgesic medication bone pain consisted ibuprofen 600 mg8 h morphine sulfate 10 mg rescue fentanyl patches discontinued January 2010 Hematological toxicity assessed 2 weeks PSA monthly The patient responded lenalidomide therapy PSA level markedly declined 391 ngml hematological cutaneous adverse events documented similar hemoglobin levels maintained lenalidomide treatment 104117 gdl The patient regained ability walk 7 daily maintaining lifestyle improved general performance status April 2010 fentanyl patches reintroduced PSA level rose 422 ngml In May 2010 increased PSA level 893 ngml accompanied clinical worsening evolution disease therapy suspended After Estracyt estramustine 140 mg12 h started response obtained PSA level July 2010 5000 ngml bone CT scans revealed lymph node liver lung metastases The progressive deterioration patients health led hospital admission death October 2010 Discussion Proliferation angiogenesis evasion immune surveillance important pathways HRPC progresses Based antiangiogenic antitumoral properties IMiDs highlight thalidomide lenalidomide new agents treating HRCP It described lenalidomide inhibits tumor necrosis factorα production diminishes levels VEGF basic fibroblast growth factor stimulates T cells hinders angiogenesis It promotes apoptosis malignant cells The antitumoral activity lenalidomide approximately 5000 times potent thalidomide animal models furthermore additional advantage associated better toxicity profile In fact preliminary studies suggest lenalidomide clinical activity patients metastatic castrationresistant prostate cancer 16 17 Nevertheless published data use lenalidomide HRPC rare far particularly chemotherapy pretreated patients All data shown clear evidence antitumor activity lenalidomide 13 14 combination docetaxel 9 12 paclitaxel 10 15 ketoconazole 11 GMCSF 8 metastatic HRPC patients Responses described studies promising regard survival advantage According experience patient described pretreated chemotherapy showed favorable response lenalidomide therapy 5 months improving general health status quality life discontinuing fentanyl administration 4 months It significant note PSA levels declined disease response pain reduction lenalidomide administration accompanied toxicity Hematological tests alteration hemoglobin levels patient experience cutaneous adverse effects This observation provides additional benefit suggests lenalidomide attractive drug antineoplastic activity low effect profile The evolution disease appearance metastases led worsening clinical situation patient Case Rep Oncol 20125181186 DOI 101159000336481 Published online April 18 2012 2012 S Karger AG Basel ISSN 16626575 wwwkargercomcro 184 The prognosis prostate cancer mainly determined presence absence metastases 18 In patient development bone lymph node liver lung metastases led progressive deterioration common complication widespread disease expansion Other treatments received patient mainly included subsequent lines hormonal therapy radiotherapy chemotherapy antineoplastic agents standard treatments management HRPC Although reductions PSA levels achieved limited period time successive changes therapy required relapse disease progression Given need new agents bear potentially high cost terms effects management HRPC patients lenalidomide proposed interesting option Conclusion In conclusion present case report presents new evidence potential lenalidomide provide clinical benefits HRPC patients antitumoral activity lack toxicity use lenalidomide supported patient population delaying disease progression Case Rep Oncol 20125181186 DOI 101159000336481 Published online April 18 2012 2012 S Karger AG Basel ISSN 16626575 wwwkargercomcro 185 Table 1 Treatment response Date Prostate cancer treatment Initial PSA ngml Final PSA ngml Clinical observations Aug99Jan08 RTCAB 197 12 Jan08Apr08 CAB Apr08Jun08 Androcur Jun08Aug08 TaxoterePred Oct08Nov08 OxiCap Nov08Mar09 Fulvestrant Mar09Aug09 Sunitinib 12 37 64 57 203 321 37 64 57 233 321 749 Aug09Sep09 Vinadriestraketo 749 1146 Oct09 Antalgic RT Nov09May10 Lenalidomide 1146 893 PSA nadir 01 ngml Bone metastases CT Castration testosterone levels Bone metastases CT Bone metastases CT Bone metastases CT Clinical deterioration Intense pain final PS 2 Bone metastases CT Clinical improvement No hematologic toxicity May10Jul10 Estracyt 1146 5000 No response Oct10 Lymph node liver lung metastases Progressive deterioration death RT Radiation therapy CAB combined androgen blockade therapy Pred prednisone Oxi oxaliplatin Cap capecitabine Vinadriestraketo vinblastineAdriamycinestramustine ketoconazole References 1 Jemal A Siegel R Ward E et al Cancer statistics 2009 CA Cancer J Clin 200959225249 2 Hamberg P Verhagen PC Wit R When start cytotoxic therapy asymptomatic patients hormone refractory prostate cancer Eur J Cancer 20084411931197 3 Sternberg CN Systemic chemotherapy new experimental approaches treatment metastatic prostate cancer Ann Oncol 200819suppl 7vii91vii95 4 Halabi S Small EJ Kantoff PW et al Prognostic model predicting survival men hormone refractory metastatic prostate cancer J Clin Oncol 20032112321237 5 Lu L Schafer P Bartlett JB Inhibition lenalidomide growth factor hypoxiainduced signaling endothelial epithelial tumor cells effects tumor cell microenvironment Proceedings Annual Meeting American Society Clinical Oncology 2009 Abstract e14620 6 Zhu D Corral LG Fleming YW et al Immunomodulatory drugs Revlimid lenalidomide CC4047 induce apoptosis hematological solid tumor cells NK cell activation Cancer Immunol Immunother 20085718491859 7 Henry J Lu L Adams M et al Lenalidomide enhances anticancer activity docetaxel vitro vivo models prostate cancer American Association Cancer Research 2010 Poster 28468 Case Rep Oncol 20125181186 DOI 101159000336481 Published online April 18 2012 2012 S Karger AG Basel ISSN 16626575 wwwkargercomcro 186 8 Garcia JA Triozzi P Smith S et al Phase III study lenalidomide GMCSF hormone refractory prostate cancer HRPC Proceedings ASCO Prostate Cancer Symposium 2007 Abstract 229 9 Moss RA Mohile SG Shelton G Melia J Petrylak DP A phase I openlabel study lenalidomide docetaxel androgen independent prostate cancer AIPC Proceedings ASCO Prostate Cancer Symposium 2007 Abstract 89 10 Pagliaro LC Tannir NM Tu S et al A modular phase I study lenalidomide paclitaxel metastatic castrationresistant prostate cancer prior taxane therapy J Clin Oncol 200826supplAbstract 13545 11 Garcia JA Triozzi P Elson P et al Clinical activity ketoconazole lenalidomide castrate progressive prostate carcinoma CPPCA preliminary results phase II trial J Clin Oncol 200826supplAbstract 5143 12 Petrylak DP RestoGarces K Tibyan M et al A phase I openlabel study lenalidomide docetaxel castrationresistant prostate cancer J Clin Oncol 200927suppl15sAbstract 5156 13 Nabhan C Tolzien K Kelby SK et al Lenalidomide Revlimid singleagent activity chemotherapynaive castrationresistant prostate cancer CRPC American Society Clinical Oncology Genitourinary Cancer Symposium Meeting 2010 Poster 14 Lestingi TM Tolzien K Kelby SK et al Safety activity lenalidomide LEN elderly patients pts chemotherapynaive castration resistant prostate cancer CRPC Proceedings Annual Meeting American Society Clinical Oncology 2010 Abstract e15125 15 Mathew P Tannir N Tu SM et al A modular phase I study lenalidomide paclitaxel metastatic castrationresistant prostate cancer following prior taxane therapy Cancer Chemother Pharmacol 201065811815 16 Dahut WL AragonChing JB Woo S et al Phase I study oral lenalidomide patients refractory metastatic cancer J Clin Pharmacol 200949650660 17 Zhu D Corral LG Fleming YW et al Immunomodulatory drugs Revlimid lenalidomide CC4047 induce apoptosis hematological solid tumor cells NK cell activation Cancer Immunol Immunother 20085718491859 18 Bubendorf L Schöpfer A Wagner U et al Metastatic patterns prostate cancer autopsy study 1589 patients Hum Pathol 200031578583